Search

Your search keyword '"Lam, Raymond W."' showing total 1,656 results

Search Constraints

Start Over You searched for: Author "Lam, Raymond W." Remove constraint Author: "Lam, Raymond W."
1,656 results on '"Lam, Raymond W."'

Search Results

1. Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volume

3. Depression-Anxiety Coupling Strength as a predictor of relapse in major depressive disorder: A CAN-BIND wellness monitoring study report

4. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder

5. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression

8. A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring Study

9. Gray matter volume drives the brain age gap in schizophrenia: a SHAP study

11. An empirical analysis of structural neuroimaging profiles in a staging model of depression

12. Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 report

17. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study

19. Advancing equitable access to digital mental health in the Asia-Pacific region in the context of the COVID-19 pandemic and beyond: A modified Delphi consensus study

20. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes

21. Alterations in the neural correlates of affective inhibitory control following cognitive behavioral therapy for depression: A Canadian biomarker integration network for depression (CAN-BIND) study

25. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

28. A Randomized Evaluation of MoodFX, a Patient-Centred e-Health Tool to Support Outcome Measurement for Depression: Une évaluation randomisée de MoodFX, un outil de santé en ligne centré sur le patient pour soutenir la mesure du résultat dans la dépression.

29. Atypical brain aging and its association with working memory performance in major depressive disorder

30. Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report

33. White matter microstructure in youth at risk for serious mental illness: A comparative analysis

35. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis

38. Comparison of the Efficacy Between Standard Measurement-Base Care (MBC) and Enhanced MBC for Major Depressive Disorder: A Pilot Study.

43. Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study

44. Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers

45. Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder

46. Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: a rapid scoping review

49. Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report

Catalog

Books, media, physical & digital resources